Form 4: Agios Pharmaceuticals Director David Schenkein Executes Stock Options and Sells Shares

Director David Schenkein exercised stock options and sold shares of Agios Pharmaceuticals in multiple transactions on February 23 and 26, 2024.

Summary

• David Schenkein, a director of Agios Pharmaceuticals, executed stock options to purchase shares of common stock at a price of $31.64 on February 23 and 26, 2024.
• On February 23, 47,731 shares were acquired through option exercise and sold at a weighted average price of $33.05, with prices ranging from $33.00 to $33.27.
• On February 26, 20,411 shares were acquired through option exercise and sold at a weighted average price of $33.19, with prices ranging from $33.00 to $33.59.
• Following these transactions, Schenkein directly owns 122,854 shares of common stock.
• Schenkein also indirectly owns 270,772 shares through the David P. Schenkein 2004 Revocable Trust and 79,082 shares through the Amy P. Schenkein 2004 Revocable Trust.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard Form 4 filing detailing stock option exercises and sales by a director. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This filing reflects routine insider transactions. Monitoring such filings provides insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership structure.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates